Nomogram M Prognostic Value for Major Adverse Cardiac and Cerebral Events after Elective Cardiac Surgery with Cardiopulmonary Bypass

The objective: to evaluate the prognostic value of Nomogram M for major adverse cardiac events (MACE) and major adverse cardiac and cerebral events (MACCE) after elective cardiac surgery with cardiopulmonary bypass.
Subjects and Methods. This is a retrospective cohort study of the Nomogram M prognostic value for MACE and MACCE after elective cardiac surgery with cardiopulmonary bypass. 158 patients were enrolled in the study. The prognostic value was estimated using ROC-analysis.
Results. The frequency of MACE and MACCE during hospitalization made 5.7% (9 of 158 patients) and 6.3% (10 of 158 patients), respectively. AUC Nomogram M for MACE was 0.888 [0.825; 0.950] (p < 0.001). Cut-off value made 12.5 points (sensitivity – 88.89%, specificity – 83.89%). Odd ratio was 41.67 [95% CI 4.98; 348.61] (p < 0.001).
AUC Nomogram M for MACCE was 0.893 [0.834; 0.951] (p < 0.001). Cut-off value made 12.5 points (sensitivity – 90.00%, specificity – 84.46%). Odd ratio was 48.91 [95% CI 5.91; 404.78] (p < 0.001)
Conclusion. Nomogram M has a good prognostic value for the occurrence of MACE and MACCE after elective cardiac surgery with cardiopulmonary bypass. For MACE sensitivity made 88.89%, and specificity – 83.89%. For MACCE sensitivity was 90.00%, specificity – 84.46%.

1. Akpek M., Kaya M.G., Lam Y.Y. et al. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am. J. Cardiol., 2012, vol. 110, no. 5, pp. 621‒627. doi:10.1016/j.amjcard.2012.04.041.

2. Baluja A., Rodríguez-Mañero M., Cordero A. et al. Prediction of major adverse cardiac, cerebrovascular events in patients with diabetes after acute coronary syndrome. Diab. Vasc. Dis. Res., 2020, vol. 17, no. 1, 1479164119892137. doi:10.1177/1479164119892137.

3. Beattie W.S., Lalu M., Bocock M. et al. Systematic review and consensus definitions for the Standardized Endpoints in Perioperative Medicine (StEP) initiative: cardiovascular outcomes. Br. J. Anaesth., 2021, vol. 126, no. 1, pp. 56‒66. doi:10.1016/j.bja.2020.09.023.

4. Berikashvili L.B., Kuzovlev A.N., Yadgarov M.Ya. et al. Influence of pre- and intraoperative factors on hospital mortality after elective cardiac surgery with cardiopulmonary bypass. A retrospective study. Ann. Crit. Care, 2021, no. 2, pp. 128-135. doi: 10.21320/1818-474X-2021-2-128-135.

5. Berikashvili L.B., Yadgarov M.Ya., Gerasimenko O.N. et al. Risk assessment of hemodynamically significant arrhythmias after elective cardiac operations with cardiopulmonary bypass using the modified nomogram (retrospective study). General Reanimatol., 2021, vol. 17, no. 6, pp. 20-26. https://doi.org/10.15360/1813-9779-2021-6-20-26.

6. Biancari F., Ruggieri V.G., Perrotti A. et al. European multicenter study on Coronary Artery Bypass Grafting (E-CABG registry): Study protocol for a prospective clinical registry and proposal of classification of postoperative complications. J. Cardiothorac. Surg., 2015, no. 10, pp. 90. Published 2015 Jun 30. doi:10.1186/s13019-015-0292-z.

7. Bosiers M.J., Tran K., Lee J.T. et al. Incidence and prognostic factors related to major adverse cerebrovascular events in patients with complex aortic diseases treated by the chimney technique. J. Vasc. Surg., 2018, vol. 67, no. 5, pp. 1372‒1379. doi:10.1016/j.jvs.2017.08.079.

8. Eknoyan G., Lameire N. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int., 2013, vol. 1, no. 3, pp. 5–14. doi:10.1038/kisup.2012.3.

9. Fellahi J.L., Le Manach Y., Daccache G. et al. Combination of EuroSCORE and cardiac troponin I improves the prediction of adverse outcome after cardiac surgery. Anesthesiology, 2011, vol. 114, no. 2, pp. 330‒339. doi:10.1097/ALN.0b013e31820166.

10. Ford M.K., Beattie W.S., Wijeysundera D.N. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. Ann. Intern. Med., 2010, vol. 152, no. 1, pp. 26‒35. doi:10.7326/0003-4819-152-1-201001050-00007.

11. Goldman L., Caldera D.L., Nussbaum S.R. et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N. Engl. J. Med., 1977, vol. 297, no. 16, pp. 845‒850. doi:10.1056/NEJM197710202971601.

12. Golubovic M., Peric V., Stanojevic D. et al. Potential new approaches in predicting adverse cardiac events one month after major vascular surgery. Med. Princ. Pract., 2019, vol. 28, no. 1, pp. 63‒69. doi:10.1159/000495079.

13. Hawn M.T., Graham L.A., Richman J.S. et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. (Published correction appears in JAMA. 2014, 311(5):528), JAMA, 2013, vol. 310, no. 14, pp. 1462‒1472. doi:10.1001/jama.2013.278787.

14. Hou Z.H., Lu B., Gao Y. et al. Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc. Imaging, 2012, vol. 5, no. 10, pp. 990‒999. doi:10.1016/j.jcmg.2012.06.006.

15. Levey A.S., Bosch J.P., Lewis J.B. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med., 1999, vol. 130, no. 6, pp. 461‒470. doi:10.7326/0003-4819-130-6-199903160-00002.

16. Lin F.J., Tseng W.K., Yin W.H. et al. Residual risk factors to predict major adverse cardiovascular events in atherosclerotic cardiovascular disease patients with and without diabetes mellitus. Sci. Rep., 2017, vol. 7, no. 1, pp. 9179. Published 2017 Aug 23. doi:10.1038/s41598-017-08741-0.

17. Nashef S.A., Roques F., Sharples L.D. et al. EuroSCORE II. Eur. J. Cardiothorac. Surg., 2012, vol. 41, no. 4, pp. 734‒745. doi:10.1093/ejcts/ezs043.

18. Sabaté S., Mases A., Guilera N. et al. Incidence and predictors of major perioperative adverse cardiac and cerebrovascular events in non-cardiac surgery. Br. J. Anaesth., 2011, vol. 107, no. 6, pp. 879‒890. doi:10.1093/bja/aer268.

19. Shon H.S., Bae J.W., Kim K.O. et al. Biomarker for the prediction of major adverse cardiac events in patients with Non-ST-Segment elevation myocardial infarction. Osong. Public Health Res. Perspect., 2017, vol. 8, no. 4, pp. 237‒246. doi:10.24171/j.phrp.2017.8.4.02.

20. Smilowitz N.R., Gupta N., Ramakrishna H. et al. Perioperative major adverse cardiovascular and cerebrovascular events associated with noncardiac surgery. JAMA Cardiol., 2017, vol. 2, no. 2, pp. 181‒187. doi:10.1001/jamacardio.2016.4792.

21. Sousa-Uva M., Head S.J., Milojevic M. et al. 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. Eur. J. Cardiothorac. Surg., 2018, vol. 53, no. 1, pp. 5-33. doi:10.1093/ejcts/ezx314.

22. Ueshima D., Ashikaga T., Yoshikawa S. et al. Effect of over-2-year dual antiplatelet therapy on the rate of major adverse cardiac and cerebral events for everolimus-eluting stent implantation: The landmark analysis from Tokyo-MD PCI registry. J. Cardiol., 2017, vol. 69, no. 6, pp. 815‒822. doi:10.1016/j.jjcc.2016.08.015.

23. Yao C., Zhou L., Huang Q. The occurrence and potential predictive factors of major adverse cardiac and cerebral events in end-stage renal disease patients on continuous ambulatory peritoneal dialysis: A prospective cohort study. Medicine (Baltimore), 2021, vol. 100, no. 10, pp. e24616. doi:10.1097/MD.0000000000024616.